New antibody aims to stop bleeding episodes in rare clotting disorder

NCT ID NCT06211634

Ongoing Disease control Sponsor: Hemab ApS Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests an experimental antibody called HMB-001 in 57 adults with Glanzmann thrombasthenia, a rare bleeding disorder. The study aims to see if the drug is safe and can reduce the number and severity of bleeds when given regularly. Participants receive single or multiple doses over several months, with close monitoring for side effects and bleeding events.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HMB-001 (a lab-made antibody given as a shot to help prevent bleeding)
What this could lead to: If it works, this could offer a way to prevent frequent, dangerous bleeds in people with Glanzmann thrombasthenia, reducing the need for emergency treatment.
What could go wrong: This is a very early first-in-human trial with only 57 people, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to reduce bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Glanzmann thrombasthenia Glanzmann thrombasthenia 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLANZMANN THROMBASTHENIA

Contacts and locations

Locations

AP-HM - Hopital de la Timone

Marseille, France
AP-HP Hopital Bicetre (Part B/C)

Le Kremlin-Bicêtre, France
AP-HP Hopital Necker-Enfants Malades (Part B/C)

Paris, France
Azienda Ospedaliero-Universitaria Careggi (Part B/C)

Florence, Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano (Part B/C)

Milan, Italy
Hemophilia Center of Western Pennsylvania (HCWP) (Part B/C)

Pittsburgh, Pennsylvania, 15213, United States
Leeds Teaching Hospitals NHS Trust

Leeds, United Kingdom
Mayo Clinic - Rochester (Part B/C)

Rochester, Minnesota, 55905, United States
Queen Elizabeth Hospital Birmingham (Part B/C)

Birmingham, United Kingdom
Richmond Pharmacology Ltd (Part A/B/C)

London, United Kingdom
Royal Free London NHS Foundation Trust (Part B/C)

London, United Kingdom
The Royal London Hospital (Part B/C)

Whitechapel, United Kingdom
Tulane University Medical Center (Part B/C)

New Orleans, Louisiana, 70112, United States
Universitair Medisch Centrum Utrecht (Part B/C)

Utrecht, Netherlands
University Hospital Leuven - Campus Gasthuisberg (Part B/C)

Leuven, Belgium
University of California, San Diego (UCSD) (Part B/C)

La Jolla, California, 92093, United States
Washington Institute for Coagulation (Part B/C)

Seattle, Washington, 98101, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.